Pfizer, BioNTech in Deal to Supply Canada With Covid-19 Vaccine Candidate
August 05 2020 - 8:55AM
Dow Jones News
By Chris Wack
Pfizer Canada and BioNTech SE said Wednesday they signed an
agreement with the government of Canada to supply their BNT162
mRNA-based vaccine candidate against SARS-CoV-2, subject to
clinical success and Health Canada approval.
Financial details of the agreement weren't disclosed, but the
terms were based on the timing of delivery and the volume of doses.
As requested by the government of Canada, deliveries of the vaccine
candidate are planned for over the course of 2021.
Pfizer and BioNTech are continuing to scale up manufacturing
capacities to be able to produce up to 100 million doses in 2020
and more than one billion doses in 2021.
The BNT162 program is based on BioNTech's proprietary mRNA
technology and supported by Pfizer's global vaccine development and
manufacturing capabilities. The vaccine development program is
evaluating at least four experimental vaccine candidates, each of
which represents a unique combination of messenger RNA format and
target antigen. The BNT162 vaccine candidates are undergoing
clinical studies and aren't currently approved for distribution
anywhere in the world.
Recently, two of the companies' four investigational vaccine
candidates -- BNT162b1 and BNT162b2 -- received Fast Track
designation from the U.S. Food and Drug Administration. This
designation was granted based on preliminary data from Phase 1/2
studies that are currently ongoing in the United States and Germany
as well as animal immunogenicity studies.
Assuming clinical success, Pfizer and BioNTech are on track to
seek regulatory review for BNT162b2 as early as October and, if
regulatory authorization or approval is obtained, plan to supply up
to 100 million doses worldwide by the end of 2020 and 1.3 billion
doses by the end of 2021.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 05, 2020 08:40 ET (12:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024